TARA

Protara Therapeutics, Inc. (TARA) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-08-01

Overall Score

Growth

No revenue base is reported in the fresh TTM metrics, so there is no evidence of scalable top-line growth.

Profitability remains absent with zero gross, operating, EBITDA, and net margins in TTM data.

Profitability

TTM returns are deeply negative, including ROA of -39.8%, ROE of -41.7%, and ROIC of -46.8%.

Operating margins remain at 0% across the reported TTM ratios, indicating no earnings power yet.

Financial Health

Liquidity is strong with a current ratio of 11.0 and cash ratio of 1.28, supported by working capital of $132.8M.

Leverage is very low with debt-to-equity of 0.017 and debt-to-assets of 0.016, though solvency ratio remains negative due to ongoing losses.

Shareholder Returns

Free cash flow remains negative at -$65.2M TTM, limiting any near-term shareholder return capacity.

No dividend is paid and earnings remain negative, so capital returns are not currently supported by fundamentals.

Valuation

Traditional earnings and cash-flow multiples are not meaningful because TTM earnings and free cash flow are negative.

Book-based valuation is the main anchor, with price-to-book at 1.44 and tangible book value per share of $2.64.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Protara Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →